Objectives: Little data are published on the unique care performance metric of electrocardiogram-to-decision time (E2Decide) for primary percutaneous coronary intervention (PCI) treatment of ST-elevation myocardial infarction (STEMI). The objective of this study is to evaluate E2Decide time on mortality and delayed reperfusion. Methods: This was a retrospective study of STEMI activations treated with primary PCI at 2 PCI-capable hospitals located in Duluth, Minnesota, and Fargo, North Dakota, originating in 3 different settings: (1) primary PCI-capable hospital emergency departments, (2) non-PCI facilities, and (3) in the field by emergency medical services. Analysis of variance, generalized linear modeling, and logistic regression models were used in this study. Results: There were 289 (96 females) STEMI patients included in our analyses. Non significant differences were observed in E2Decide time between male and female patients (9.7 vs. 11.1 min, respectively). Generalized linear modeling revealed that only non-PCI facilities significantly affected E2Decide time [β = 6.29; P = 0.007; 95% confidence interval (CI), 1.7–10.9] relative to PCI-capable hospitals. We found that E2Decide time was significantly associated with the metric decision-to-PCI, and that for every additional E2Decide minute, the decision-to-PCI increased by another 1.21 minutes (P < 0.001; 95% CI, 0.873–1.56). We also found a 20.3% increased odds of 30-day mortality for every 5-minute increase in E2Decide time (estimated odds ratio = 1.20; 95% CI, 1.04–1.38). Conclusions: We observed that a delay in E2Decide time was significantly associated with a subsequent delay in decision-to-PCI time. E2Decide time was significantly associated with increased odds in 30-day mortality. This study demonstrates the potential value of the metric E2Decide time.
Critical Pathways in Cardiology – Wolters Kluwer Health
Published: Mar 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud